GHRP-2 is a synthetic hexapeptide researchers find studied as a growth hormone secretagogue. It stimulates GH release by binding the ghrelin receptor GHS-R1a directly at the pituitary. Researchers observe it act through the same mechanism as GHRP-6, and it synergizes with GHRH in experimental models. Researchers track GH, IGF-I, and IGFBP readouts across rat cells, knockout mice, and human infusion protocols. There’s more to know about how GHRP-2 works below. Ipamorelin in research models has shown promise in enhancing growth hormone levels similarly to other secretagogues. Its efficacy is being evaluated through various biochemical assays and in different animal studies.
Key Takeaways
- GHRP-2 is a synthetic hexapeptide that stimulates growth hormone release by acting on the ghrelin/GHS-R1a receptor at the pituitary level.
- It shares the same receptor and mechanism as GHRP-6 and synergizes with GHRH, though combined maximal doses don’t exceed either peptide alone.
- In lit/lit mice, 10 mcg GHRP-2 raised GH to 9.3 ng/mL versus 1.04 ng/mL in controls (p < 0.001).
- Human research uses provocative testing, overnight profiles, and 30-day infusions, tracking pulsatile GH, IGF-I, IGFBP-3, and IGFBP-5.
- Beyond GH, GHRP-2 also raises prolactin, ACTH, and cortisol, while showing no structural homology to GHRH.
What is GHRP-2 in growth hormone release research
GHRP-2 is a synthetic hexapeptide classified as a growth hormone secretagogue, studied for its capacity to stimulate GH release. It acts through the ghrelin/growth hormone secretagogue receptor (GHS-R1a), showing activity directly at the pituitary level. In rat pituitary cells, it stimulates GH release through the same receptor and mechanism as GHRP-6. It synergizes with growth hormone-releasing factor (GRF/GHRH), though co-administering maximal concentrations of both doesn’t exceed the effect of either peptide alone. Comparative work has identified GHRP-2 as a potent GH secretagogue despite sharing no structural homology with GHRH. This receptor-specific action makes GHRP-2 a valuable tool for probing somatotroph responsiveness and ghrelin-mediated pituitary signaling pathways.
How does GHRP-2 stimulate GH release in models
GHRP-2 stimulates GH release by acting at the pituitary through the ghrelin/growth hormone secretagogue receptor (GHS-R1a), using the same receptor and mechanism as GHRP-6. In rat pituitary cells, this shared pathway drives GH release despite GHRP-2 sharing no structural homology with GHRH. Across experimental models, researchers have measured GHRP-2’s GH-stimulating activity to quantify somatotroph responsiveness. Researchers also observe synergy with GRF/GHRH, though co-administering maximal concentrations of both won’t exceed either peptide’s effect alone. In lit/lit mice, 10 mcg GHRP-2 raised GH to 9.3 ± 1.5 ng/mL versus 1.04 ± 1.15 ng/mL in controls (p < 0.001). This confirms potent secretagogue activity. When researchers interpret these findings, researchers are observing receptor-mediated somatotroph stimulation that’s consistent across species, establishing GHRP-2 as a reliable GH-releasing probe.
Which receptor does GHRP-2 target
GHRP-2 targets the ghrelin/growth hormone secretagogue receptor, or GHS-R1a. When researchers administer GHRP-2, this synthetic hexapeptide binds GHS-R1a and triggers GH release at the pituitary level. Researchers notice it works through the same receptor and mechanism as GHRP-6, confirming a shared secretagogue pathway. In rat pituitary cells, GHRP-2 stimulates GH via this receptor despite sharing no structural homology with GHRH. That’s significant, because it means researchers are engaging a distinct signaling route that still synergizes with GHRH. When researchers co-administer maximal concentrations, though, the combined effect won’t exceed either peptide alone, suggesting a shared downstream ceiling. By targeting GHS-R1a, GHRP-2 also functions as a ghrelin-mimetic, explaining its parallel effects on appetite and metabolism.
How is GHRP-2 studied in research
GHRP-2 is studied across multiple models to isolate its effects on GH secretion, because it acts at a well-defined receptor. Researchers find work spanning rat pituitary cells, where GHRP-2 stimulates GH through the same receptor and mechanism as GHRP-6, and lit/lit mice, where a 10 mcg dose raised GH to 9.3 ± 1.5 ng/mL versus 1.04 ± 1.15 ng/mL in controls. In GHRH-knockout mice, researchers can test whether chronic GHRP-2 drives longitudinal growth and somatotroph proliferation. Human studies use provocative testing, overnight secretion profiles, and 30-day continuous subcutaneous infusion to track pulsatile GH, IGF-I, IGFBP-3, and IGFBP-5. Researchers also examine synergy with GHRH, appetite responses, and ACTH release, letting researchers separate direct pituitary actions from downstream anabolic and metabolic effects.
How does GHRP-2 compare to GHRP-6
GHRP-2 and GHRP-6 are two hexapeptides that hit the same target: the ghrelin/growth hormone secretagogue receptor (GHS-R1a). In rat pituitary cells, GHRP-2 stimulates GH release through the same receptor and mechanism as GHRP-6. Both synergize with GHRH, though combining maximal concentrations won’t exceed either peptide alone. GHRP-2 is characterized as a potent secretagogue despite lacking structural homology with GHRH. The debate between pulsatile vs continuous GH administration is crucial in understanding growth hormone dynamics. Research indicates that pulsatile delivery may better mimic the natural secretion patterns of GH, leading to enhanced physiological effects.
| Feature | GHRP-2 | GHRP-6 |
|---|---|---|
| Receptor | GHS-R1a | GHS-R1a |
| Mechanism | Shared | Shared |
| GHRH synergy | Yes | Yes |
| Potency | Potent | Comparable |
Beyond GH, GHRP-2 and hexarelin raise prolactin, ACTH, and cortisol in men. Either peptide probes overlapping ghrelin-mimetic signaling driving GH release and appetite. Ipamorelin vs ghrp-2 vs ghrp-6 selectivity plays a crucial role in determining their pharmacological applications.
How to source research-grade GHRP-2
Source research-grade GHRP-2 by matching the peptide to the experimental endpoints, since the compound’s short half-life (~0.52 hours) and low oral availability (0.30 to 1.0%) constrain how researchers design dosing and administration. Because GHRP-2 acts through GHS-R1a to drive pituitary GH release, and secondarily ACTH, prolactin, and cortisol, researchers want confirmed peptide identity and purity so the hormonal readouts reflect receptor-specific activity, not contaminants. Request HPLC and mass spectrometry documentation verifying the hexapeptide sequence and quantifying purity. Confirm proper lyophilization and cold storage, since peptide degradation shifts the effective dose. Given the brief duration of action, researchers typically plan subcutaneous or infusion protocols rather than oral routes. Match lot consistency to longitudinal studies, and verify labeling specifies research-only use for compliance.
Shop GH Secretagogues at Holas
From GHRP-2 to Ipamorelin to CJC-1295, comparing receptor selectivity requires research-grade peptides with verified purity. Holas supplies laboratory-grade Ipamorelin and CJC-1295 peptides, third-party tested and prepared for research use. Browse our shop or contact us to source the right peptides for the work.
Frequently Asked Questions
Does GHRP-2 Affect Appetite or Food Intake in Research Subjects?
Yes. Acting as a ghrelin-mimetic through the GHS-R1a receptor, GHRP-2 increased appetite and food intake in reported studies. In healthy men, food intake rose about 35.9 ± 10.9% versus saline. In obese subjects the effect was dose-dependent, roughly 10.2 ± 3.9% at a low dose and 33.5 ± 5.8% at a high dose. This appetite stimulation is a recognized biologic effect, and reported findings describe it as typically transient.
Can GHRP-2 Stimulate ACTH and Cortisol Besides Growth Hormone?
Yes. Alongside growth hormone, GHRP-2 raised GH, prolactin, ACTH, and cortisol levels in reported studies, and mouse pituitary work showed it directly promotes ACTH secretion and synthesis. The GHRP-2 test can induce ACTH release, indicating screening utility for pituitary adrenal insufficiency, reported at a 1.55-fold cutoff, 83% sensitivity, and 88% specificity. Because of this, GH and ACTH are typically evaluated together so secondary adrenal insufficiency is not missed.
What Is GHRP-2’s Oral Bioavailability and Half-Life?
GHRP-2’s oral bioavailability is low, ranging from about 0.30 to 1.0%, and its half-life is short at roughly 0.52 hours. Oral delivery therefore provides little meaningful systemic exposure, and the peptide clears rapidly once in circulation. Because of this brief duration of action, alternative formulations or delivery routes are generally required to sustain GHS-R1a activation and prolong the hormonal response under study.
Was GHRP-2 Well Tolerated in Pediatric Research Trials?
Yes. Reported pediatric research trials described GHRP-2 as well tolerated. In one study, no side effects or toxicities were observed despite active GH stimulation, and intranasal delivery in children with growth failure was likewise described as well tolerated. Reported effects such as transient appetite increase and transient cortisol elevation reflect its ghrelin-mimetic and ACTH-promoting actions but did not compromise overall pediatric tolerability.
Does GHRP-2 Reliably Increase IGF-I and IGFBP-3 Levels?
Not consistently. The response depends on exposure duration. With short-term pediatric dosing, studies reported GH stimulation but no rise in IGF-I or IGFBP-3, so the acute hormonal response does not always translate downstream. With 30-day continuous subcutaneous infusion in older subjects, however, studies reported sustained pulsatile GH along with increased IGF-I, IGFBP-3, and IGFBP-5.
